233 related articles for article (PubMed ID: 20423991)
1. SKI-606 (Bosutinib) blocks prostate cancer invasion, growth, and metastasis in vitro and in vivo through regulation of genes involved in cancer growth and skeletal metastasis.
Rabbani SA; Valentino ML; Arakelian A; Ali S; Boschelli F
Mol Cancer Ther; 2010 May; 9(5):1147-57. PubMed ID: 20423991
[TBL] [Abstract][Full Text] [Related]
2. A Src/Abl kinase inhibitor, SKI-606, blocks breast cancer invasion, growth, and metastasis in vitro and in vivo.
Jallal H; Valentino ML; Chen G; Boschelli F; Ali S; Rabbani SA
Cancer Res; 2007 Feb; 67(4):1580-8. PubMed ID: 17308097
[TBL] [Abstract][Full Text] [Related]
3. An anti-urokinase plasminogen activator receptor antibody (ATN-658) blocks prostate cancer invasion, migration, growth, and experimental skeletal metastasis in vitro and in vivo.
Rabbani SA; Ateeq B; Arakelian A; Valentino ML; Shaw DE; Dauffenbach LM; Kerfoot CA; Mazar AP
Neoplasia; 2010 Oct; 12(10):778-88. PubMed ID: 20927316
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts.
Messersmith WA; Rajeshkumar NV; Tan AC; Wang XF; Diesl V; Choe SE; Follettie M; Coughlin C; Boschelli F; Garcia-Garcia E; Lopez-Rios F; Jimeno A; Hidalgo M
Mol Cancer Ther; 2009 Jun; 8(6):1484-93. PubMed ID: 19509264
[TBL] [Abstract][Full Text] [Related]
5. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo.
Shukeir N; Stefanska B; Parashar S; Chik F; Arakelian A; Szyf M; Rabbani SA
Br J Pharmacol; 2015 Jun; 172(11):2769-81. PubMed ID: 25631332
[TBL] [Abstract][Full Text] [Related]
7. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
8. SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells.
Vultur A; Buettner R; Kowolik C; Liang W; Smith D; Boschelli F; Jove R
Mol Cancer Ther; 2008 May; 7(5):1185-94. PubMed ID: 18483306
[TBL] [Abstract][Full Text] [Related]
9. Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer.
Feeley BT; Gamradt SC; Hsu WK; Liu N; Krenek L; Robbins P; Huard J; Lieberman JR
J Bone Miner Res; 2005 Dec; 20(12):2189-99. PubMed ID: 16294272
[TBL] [Abstract][Full Text] [Related]
10. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models.
Golas JM; Lucas J; Etienne C; Golas J; Discafani C; Sridharan L; Boghaert E; Arndt K; Ye F; Boschelli DH; Li F; Titsch C; Huselton C; Chaudhary I; Boschelli F
Cancer Res; 2005 Jun; 65(12):5358-64. PubMed ID: 15958584
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of noggin inhibits BMP-mediated growth of osteolytic prostate cancer lesions.
Feeley BT; Krenek L; Liu N; Hsu WK; Gamradt SC; Schwarz EM; Huard J; Lieberman JR
Bone; 2006 Feb; 38(2):154-66. PubMed ID: 16126463
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells.
Puttini M; Coluccia AM; Boschelli F; Cleris L; Marchesi E; Donella-Deana A; Ahmed S; Redaelli S; Piazza R; Magistroni V; Andreoni F; Scapozza L; Formelli F; Gambacorti-Passerini C
Cancer Res; 2006 Dec; 66(23):11314-22. PubMed ID: 17114238
[TBL] [Abstract][Full Text] [Related]
13. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
Golas JM; Arndt K; Etienne C; Lucas J; Nardin D; Gibbons J; Frost P; Ye F; Boschelli DH; Boschelli F
Cancer Res; 2003 Jan; 63(2):375-81. PubMed ID: 12543790
[TBL] [Abstract][Full Text] [Related]
14. Abrogation of transforming growth factor-β-induced tissue fibrosis in TBRIcaCol1a2Cre transgenic mice by the second generation tyrosine kinase inhibitor SKI-606 (Bosutinib).
Wermuth PJ; Jimenez SA
PLoS One; 2018; 13(5):e0196559. PubMed ID: 29718973
[TBL] [Abstract][Full Text] [Related]
15. Suppression of invasion and metastasis of prostate cancer cells by overexpression of NDRG2 gene.
Gao L; Wu GJ; Liu XW; Zhang R; Yu L; Zhang G; Liu F; Yu CG; Yuan JL; Wang H; Yao LB
Cancer Lett; 2011 Nov; 310(1):94-100. PubMed ID: 21741166
[TBL] [Abstract][Full Text] [Related]
16. LRP5 knockdown: effect on prostate cancer invasion growth and skeletal metastasis in vitro and in vivo.
Rabbani SA; Arakelian A; Farookhi R
Cancer Med; 2013 Oct; 2(5):625-35. PubMed ID: 24403228
[TBL] [Abstract][Full Text] [Related]
17. Synergism between bosutinib (SKI-606) and the Chk1 inhibitor (PF-00477736) in highly imatinib-resistant BCR/ABL⁺ leukemia cells.
Nguyen T; Hawkins E; Kolluri A; Kmieciak M; Park H; Lin H; Grant S
Leuk Res; 2015 Jan; 39(1):65-71. PubMed ID: 25465126
[TBL] [Abstract][Full Text] [Related]
18. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer.
Sankpal UT; Abdelrahim M; Connelly SF; Lee CM; Madero-Visbal R; Colon J; Smith J; Safe S; Maliakal P; Basha R
Prostate; 2012 Nov; 72(15):1648-58. PubMed ID: 22473873
[TBL] [Abstract][Full Text] [Related]
19. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
20. Bosutinib.
Keller G; Schafhausen P; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
